TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+5.43%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$3.11B
AUM Growth
+$3.11B
(+0.07%)
Cap. Flow
-$18.4M
Cap. Flow
% of AUM
-0.59%
Top 10 Holdings %
Top 10 Hldgs %
35.29%
Holding
188
New
16
Increased
27
Reduced
40
Closed
17
Top Buys
| 1 |
Pfizer
PFE
|
$42.6M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$29.7M |
| 3 |
Moderna
MRNA
|
$22.1M |
| 4 |
Danaher
DHR
|
$17.7M |
| 5 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
$16.4M |
Top Sells
| 1 |
Biogen
BIIB
|
$23.6M |
| 2 |
Exact Sciences
EXAS
|
$21.5M |
| 3 |
CTLT
CATALENT, INC.
CTLT
|
$19.2M |
| 4 |
Cigna
CI
|
$18M |
| 5 |
Dentsply Sirona
XRAY
|
$17.3M |
Sector Composition
| 1 | Healthcare | 96.33% |
| 2 | Real Estate | 2.82% |
| 3 | Industrials | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
UnitedHealth
UNH
$281B
| $161M | 5.18% | 320,354 +14,225 | +5% | +$7.14M |
|
|
2
Moderna
MRNA
$9.37B
| $139M | 4.47% | 546,624 +87,168 | +19% | +$22.1M |
|
3
Amgen
AMGN
$155B
| $129M | 4.16% | 574,918 | – | – |
|
4
Gilead Sciences
GILD
$140B
| $122M | 3.94% | 1,686,565 -21,500 | -1% | -$1.56M |
|
5
Thermo Fisher Scientific
TMO
$186B
| $102M | 3.27% | 152,326 +6,210 | +4% | +$4.14M |
|
|
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $96.7M | 3.11% | 897,540 -12,800 | -1% | -$1.38M |
|
7
Regeneron Pharmaceuticals
REGN
$61.5B
| $90.3M | 2.91% | 143,049 -4,966 | -3% | -$3.14M |
|
8
Johnson & Johnson
JNJ
$427B
| $88.4M | 2.84% | 516,652 | – | – |
|
9
Illumina
ILMN
$15.8B
| $86.1M | 2.77% | 226,212 +32,249 | +17% | +$12.3M |
|
10
Abbott
ABT
$231B
| $82.1M | 2.64% | 583,277 -73,761 | -11% | -$10.4M |
|
|
11
Pfizer
PFE
$141B
| $69.2M | 2.23% | 1,171,903 +721,524 | +160% | +$42.6M |
|
12
AbbVie
ABBV
$372B
| $69M | 2.22% | 509,817 -14,396 | -3% | -$1.95M |
|
|
13
Danaher
DHR
$147B
| $66.6M | 2.14% | 202,360 +53,677 | +36% | +$17.7M |
|
14
Eli Lilly
LLY
$657B
| $63.7M | 2.05% | 230,432 -45,000 | -16% | -$12.4M |
|
|
SGEN
15
DELISTED
Seagen Inc. Common Stock
SGEN
| $61.8M | 1.99% | 399,527 +192,193 | +93% | +$29.7M |
|
16
Merck
MRK
$210B
| $60.4M | 1.94% | 788,122 -28,183 | -3% | -$2.16M |
|
17
Vertex Pharmaceuticals
VRTX
$100B
| $60M | 1.93% | 273,046 | – | – |
|
18
Idexx Laboratories
IDXX
$51.8B
| $52.5M | 1.69% | 79,663 | – | – |
|
19
Medtronic
MDT
$119B
| $52.3M | 1.68% | 505,860 -94,862 | -16% | -$9.81M |
|
20
Stryker
SYK
$150B
| $49.1M | 1.58% | 183,582 +33,082 | +22% | +$8.85M |
|
21
McKesson
MCK
$85.4B
| $46.9M | 1.51% | 188,522 +6,945 | +4% | +$1.73M |
|
22
Bristol-Myers Squibb
BMY
$96B
| $46.6M | 1.5% | 747,043 +134,807 | +22% | +$8.41M |
|
23
AstraZeneca
AZN
$248B
| $45.9M | 1.48% | 787,485 -25,442 | -3% | -$1.48M |
|
|
SYNH
24
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $41.4M | 1.33% | 403,087 +159,454 | +65% | +$16.4M |
|
25
Guardant Health
GH
$8.41B
| $35.2M | 1.13% | 351,484 -36,500 | -9% | -$3.65M |
|